556 results on '"Ribera, J. M."'
Search Results
2. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
3. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
4. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.
5. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma
6. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT
7. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia
8. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
9. P1702: IMPACT OF CENTER CHARACTERISTICS AND MACROECONOMIC FACTORS ON THE OUTCOME OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC-INSPIRED PROTOCOLS
10. PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
11. P569: GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY
12. Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial
13. Treatment of High-Risk Acute Lymphoblastic Leukemia. Preliminary Results of the Protocol PETHEMA ALL-93
14. PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study
15. Managing hematological cancer patients during the COVID-19 pandemic:an ESMO-EHA Interdisciplinary Expert Consensus
16. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
17. CD34(+)CD19(-)CD22(+) B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
18. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
19. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT
20. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia
21. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk
22. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML
23. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
24. The commitment and evaluation of the quality management plan by professionals from accredited stem cell transplant centers in Spain
25. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies
26. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL
27. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
28. CONDITIONING REGIMEN WITH HIGH DOSE MELPHALAN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS: COMPARISON BETWEEN ONE DAY VERSUS TWO DAYS ADMINISTRATION: PH-AB032
29. COMPARISON OF LEVOFLOXACIN PROPHYLAXIS VERSUS NO PROPHYLAXIS IN PATIENTS RECEIVING AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. RETROSPECTIVE COHORT STUDY FROM A SINGLE CENTER: PH-P465
30. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy
31. INTRAVENOUS HIGH DOSE METHOTREXATE AS CENTRAL NERVOUS SYSTEM (CNS) PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) WITH HIGH RISK FOR CNS PROGRESSION
32. BRENTUXIMAB VEDOTIN PLUS CHP AS FIRST‐LINE TREATMENT IN CD30 + PERIPHERAL T‐CELL LYMPHOMAS: REAL LIFE EXPERIENCE FROM A SINGLE INSTITUTION IN SPAIN
33. R‐GDP SCHEDULE IN PATIENTS WITH REFRACTORY OR RELAPSED B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)
34. DOUBLE‐HIT (DHL) AND TRIPLE‐HIT LYMPHOMAS (THL): REAL LIFE EXPERIENCE OF 46 CONSECUTIVE PATIENTS FROM A SINGLE INSTITUTION IN SPAIN
35. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
36. Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source
37. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
38. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells
39. Unrelated cord blood transplant for adult with primary acute myeloid leukaemia. A survey by EUROCORD and the Acute Leukaemia Working party of the EBMT: P911
40. Prognosis of multiple myeloma patients after autologous stem cell transplantation in the last decade. Comparison of two cohorts with different induction treatment approaches: P890
41. Evaluation of the implementation of JACIE standards by the personnel involved in a haematopoietic stem cell transplantation unit: P829
42. Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics
43. Predictive factors for relapse in adult patients with high-risk acute lymphoblastic leukaemia submitted to an unrelated haematopoietic progenitor transplant: O139
44. The Impact of Age in the Long-Term Outcome of Patients with Newly Diagnosed Multiple Myeloma: A502
45. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
46. Neutropenic enterocolitis in adult patients with acute leukaemia and in stem cell transplant recipients: study of 9 cases
47. Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis
48. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems
49. Usefulness of procalcitonin measurement for the diagnosis of febrile neutropenia in patients undergoing stem cell transplantation
50. Allogeneic transplant with reduced-intensity conditioning regimens could overcome poor prognosis of unmutated 11q- or 17p- B chronic lymphocytic leukaemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.